Actively Recruiting
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Led by Chinese PLA General Hospital · Updated on 2026-04-02
12
Participants Needed
1
Research Sites
282 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.
CONDITIONS
Official Title
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 14 to 75 years, any gender
- Diagnosed with blood cancers and received allogeneic hematopoietic stem cell transplantation
- Have Epstein-Barr virus infection after the transplantation
- Karnofsky score of 70 or higher if age 16 or older, or Lansky score of 50 or higher if under 16
- TCR-T cell donors aged 8 to 70 years who understand and consent to the study
- Donors must have at least 3 out of 6 HLA matches with recipients
- Donors must have lymphocyte counts between 0.8 and 4 x 10^9/L
- Donors must have good vein access and no symptoms preventing blood collection
You will not qualify if you...
- Uncontrolled active acute graft-versus-host disease one day before infusion
- Severe kidney disease (creatinine over 3 times normal), liver damage (high bilirubin or liver enzymes), or severe heart failure one week before infusion
- Expected use of immunosuppressive hormones on infusion day
- Presence of other cancers
- Relapsed or uncontrolled blood cancers
- Positive for HIV antibodies or TAP antibodies
- Pregnant or breastfeeding women
- Expected to receive other cell therapies within 4 weeks after infusion
- Participation in other drug or medical device studies within 30 days before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
D
Daihong Liu, Doctor
CONTACT
L
Liping Dou, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here